Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
Hexarelin demonstrates excellent safety with minimal side effects at standard 50-100 mcg doses. Possible mild effects include transient injection site redness, temporary carpal tunnel-like paresthesias, and minimal cortisol elevation. Contraindicated in active cancer, pregnancy, and severe diabetes. No serious adverse events reported at research dosages.
Safety Profile Overview
Hexarelin has been studied for 30+ years with consistent findings of excellent tolerability. No cases of serious adverse events at research dosages (50-200 mcg twice weekly). The peptide is well-tolerated across ages, sexes, and diverse health populations. Understanding the actual risks vs. hypothetical concerns helps users make informed decisions.
Cortisol Response: The Major Safety Advantage
Unlike GHRP-2 and GHRP-6, hexarelin produces minimal cortisol elevation. Research shows cortisol increases 10-15% above baseline vs. 40-60% for other GHRP variants. This is clinically significant because elevated cortisol accelerates protein breakdown and fat deposition, potentially negating GH benefits. Hexarelin's low cortisol response is one of its primary advantages over alternatives.
Glucose and Insulin Effects
Theoretical concern: Growth hormone elevation can impair glucose tolerance. Actual data: Research shows hexarelin produces no clinically significant changes in fasting glucose, HbA1c, or insulin sensitivity at research dosages. Some users show improved glucose tolerance (likely from improved body composition). Safe for individuals with well-controlled diabetes; not recommended for uncontrolled diabetes.
Carpal Tunnel Risk
Very rare at standard dosages. Carpal tunnel-like symptoms (hand tingling) occur in 1-3% of users, typically at excessive doses (>150 mcg per injection). Symptoms are transient (hours to days) and resolve with dose reduction. This is distinct from true carpal tunnel syndrome (which requires weeks to develop). Risk is minimized by appropriate dosing and monitoring.
Contraindications: When NOT to Use Hexarelin
Absolute: Active cancer (any type), pregnancy, nursing mothers, uncontrolled diabetes or significant hyperglycemia.
Relative (use with caution): History of cancer (risk is theoretical but warrants provider discussion), severe sleep apnea (GH may worsen), uncontrolled hypertension, significant cardiovascular disease.
Long-Term Safety: Beyond 12 Weeks
Limited long-term data, but available research (24-52 week studies) shows no unexpected safety issues with extended use. Most practitioners recommend cycling (e.g., 12-16 weeks on, 4-8 weeks off) to prevent potential tolerance and provide body breaks. This cycling approach has no known safety downsides and likely optimizes long-term risk-benefit.
Monitoring Recommendations
Baseline: Blood work (glucose, lipids, liver/kidney function). Mid-protocol (6-8 weeks): None required for healthy individuals; optional cortisol and IGF-1 measurement. End of protocol: Repeat baseline blood work. Annual: Comprehensive physical if using long-term.
Injection Safety
Subcutaneous injection is standard and safest route. Intramuscular injection also safe but provides no benefit. Intravenous injection not recommended (no data supporting benefit and potential for systemic effects). Proper injection technique (sterile needle, clean injection site, appropriate depth) is essential. Users should be trained on injection protocol.
Interactions with Medications
No significant drug interactions documented. Safe with: testosterone, hormonal contraceptives, thyroid medications, common supplements. Theoretical interactions with diabetes medications (improved glucose control might require dose adjustment); consult healthcare provider if diabetic.